SOURCE: DNAPrint Genomics, Inc.

June 23, 2006 07:00 ET

DNAPrint Genomics Researcher Lectures at California Department of Justice Seminar

SARASOTA, FL -- (MARKET WIRE) -- June 23, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) announced that Jason Eshleman, Ph.D., Senior Research Director at the Company's Trace Genetics subsidiary, is a scheduled guest lecturer for today's session of a course titled "Genetics Law and Society" offered by the California Department of Justice.

The two-day course, which began on Thursday, was organized by the California Criminalistics Institute, a unit of the California Department of Justice, Bureau of Forensic Services, and is being held at its DNA laboratories in Richmond, Calif.

"Phenotype Profiling," the topic of Dr. Eshleman's lecture, addresses issues related to genetic typing, ancestry, and the scientific basis for the Company's DNAWitness™ forensics technology for law enforcement. His lecture is part of a seminar designed to offer an introduction to the legal, societal, and bioethical issues that arise as a result of advances in genetics.

"We are pleased that Dr. Eshleman was chosen to participate in this course," said DNAPrint President and Chief Executive Officer Richard Gabriel. "Our DNAWitness technology is utilized by California authorities in a number of criminal investigations. We are pleased that DNAWitness is being used in the course as an example of current DNA technology and its potential for law enforcement."

"Genetics, Law and Society" provides an introduction to the legal, societal, and bioethical issues that arise from advances in genetics. Major topic areas include: advances in forensic genetics, genetic privacy and databanks, and selected applications in medical genetics. It is intended for criminal justice professionals who use DNA to solve crimes, including forensic scientists, criminalists, laboratory managers and other crime laboratory personnel.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness™, RETINOME™, AncestrybyDNA™ and EuroDNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400
    -or-
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848